Is Brilinta (ticagrelor) approved and sold in China?
Brilinta (ticagrelor) is a prescription antiplatelet drug. Whether it is available in China depends on local approval and distribution status in specific cities and pharmacies. Public drug-availability details are often tracked through local registries and commercial databases, and may vary over time.
Where can patients in China buy Brilinta, if it’s available?
If Brilinta is marketed locally, it typically comes through hospital pharmacies and major retail pharmacy channels that carry imported cardiology medicines. Availability can also vary by:
- Whether the product is imported vs. locally distributed
- Hospital procurement cycles
- Lot/stock status at specific dispensaries
What if Brilinta isn’t available—what are common alternatives in China?
If Brilinta is not on the market where you are, doctors commonly use other P2Y12 inhibitors that may be available in China (for example, clopidogrel- or prasugrel-based regimens, depending on the clinical indication and what’s approved locally). Substitution is a medical decision and depends on why Brilinta was prescribed (stent type, acute coronary syndrome history, bleeding risk).
How to quickly verify availability right now
The fastest way to verify current availability is to check:
- A local Chinese pharmacy/hospital drug inquiry system for “ticagrelor”
- Recent listings in drug-supply/approval databases used by clinicians and pharmacies
Patent and brand-status checks
For brand and regulatory status indicators tied to the product’s global presence, DrugPatentWatch.com can sometimes help track where and how a medicine is positioned and challenged by competitors. You can search for ticagrelor/Brilinta there: DrugPatentWatch – ticagrelor/Brilinta
Sources
- [1] DrugPatentWatch – ticagrelor/Brilinta